Advertisement RedHill Biopharma gets notice of allowance for new Israeli patent covering RHB-104 to treat Crohn's disease - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

RedHill Biopharma gets notice of allowance for new Israeli patent covering RHB-104 to treat Crohn’s disease

RedHill Biopharma has received a Notice of Allowance from the Israeli Patent Office (ILPO) for a new Israeli patent No. 207420 covering the formulation of RHB-104, a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties.

The Israeli patent application No. 207420 is entitled "Methods and Compositions for Treating Inflammatory Bowel Disease". Once granted, the patent is expected to be valid through at least 2029.

The new patent allowance in Israel further extends the geographic reach of RedHill’s intellectual property for RHB-104 and is an addition to already granted U.S. patents and pending filings in other countries.

RHB-104 is currently undergoing a first Phase III study for Crohn’s disease in the U.S. and additional countries, including Israel (the MAP US study), and a second Phase III study (the MAP EU study) is planned to be conducted in selected European countries in parallel with the ongoing MAP US Phase III study.

Interim analysis of the ongoing randomized, double-blind, placebo-controlled MAP US Phase III study is expected in the second half of 2016, after half of the 270 patients planned to be enrolled in the study will have completed 26 weeks of treatment.

RHB-104 is also being evaluated as a treatment for relapsing-remitting multiple sclerosis (RRMS). The last patient has been enrolled in an open label Phase IIa, proof-of-concept clinical study evaluating RHB-104 as an add-on therapy to interferon beta-1a in patients treated for RRMS (the CEASE-MS study).

Top-line interim results are expected either in the fourth quarter of 2015 or the first quarter of 2016.

The MAP US Phase III study is registered on www.ClinicalTrials.gov, a web-based service of the U.S. National Institutes of Health, which provides access to information on publicly and privately supported clinical studies.

Currently in a first Phase III study for the treatment of Crohn’s disease (the MAP US study) and a second Phase III study being prepared (the MAP EU study), RHB-104 is a proprietary and potentially groundbreaking antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties.

RHB-104 is based on increasing evidence supporting the hypothesis that Crohn’s disease is caused by the Mycobacterium avium subspecies paratuberculosis (MAP) infection in susceptible patients. Clinical trials conducted with earlier formulations of RHB-104 include an Australian Phase III study conducted by Pfizer.

RedHill has conducted several supportive studies with the current formulation of RHB-104, and a long-term population pharmacokinetic (Pop-PK) study is ongoing as part of the Phase III MAP US study. RHB-104 is covered by several issued and pending patents. RedHill is also conducting an open label Phase IIa, proof-of-concept clinical study, evaluating RHB-104 as an add-on therapy to interferon beta-1a in patients treated for relapsing-remitting multiple sclerosis (RRMS).